J&J’s Contineum-partnered depression drug flunks another phase 2 test

Posted inBiotechnology

A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate.